Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Facit exited McMaster University's cancer radiotherapy spinout in an upsized initial public offering after $158m in funding.

OneProjects, an irregular heartbeat imaging system developer assisted by two Irish universities, will use the cash to pursue commercialisation in the US.

University of Kent's UltraSoc Technologies, which provides integrated circuit safety technologies, has agreed to an acquisition by Siemens.

The corporate has donated $200,000 to bring University of Michigan philanthropic seed fund Accelerate Blue halfway toward its $2m initial target.

Oncology treatment developer Relay Therapeutics is advancing research from several universities and has now filed for a $200m IPO.

The UCL and Ludwig Institute-linked cancer immunotherapy developer has raised more than $200m in funding and has filed to raise up to $100m.

Sethuraman Panchanathan has been appointed the new director of the US National Science Foundation, having previously held executive positions at ASU.

Gilead Sciences will invest $275m for a 49.9% stake in the UofT and UCSF-linked company as part of a $1.47bn deal to potentially purchase Pionyr outright.

Sana Biotechnology has closed its first round with more than $700m after investors including GV swung behind its vision to commercialise cell therapies.